EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk

Mar Masiá iD, Marta Fernández-González iD, Christian Ledesma iD, Maria Losada-Echeberría iD, Nieves Gonzalo-Jiménez iD, Paula Mascarell iD, Javier García-Abellán iD, Leandro López iD, Melissa Bello-Pérez iD, Sergio Padilla iD, Felix Gutiérrez iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Mar Masiá und 10 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, HIV-1, Virus Shedding. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The impact of long-acting injectable cabotegravir plus rilpivirine (CAB/RPV) on rectal human immunodeficiency virus 1 (HIV-1) RNA dynamics and the factors associated with viral shedding remain poorly understood.

Methods

This prospective study evaluated HIV-1 RNA dynamics by analyzing sequential paired plasma and rectal fluid samples from virologically suppressed individuals who transitioned from oral antiretroviral therapy (ART) to every-2-month CAB/RPV (preceded or not by oral lead-in), over a 9-month follow-up period. RPV trough concentrations were measured in 384 rectal samples.

Results

In total, 597 plasma and 561 rectal samples from 90 participants were analyzed. HIV-1 RNA >50 (>1.69 log10) copies/swab was detected in 14.7% (59/401) of rectal samples (42.2% of participants) during intramuscular CAB/RPV, and in 17.5% (28/160) of rectal samples (29% of participants) during oral ART. Median detectable rectal HIV-1 RNA level during intramuscular ART was 362 (range, 133–2216) copies/swab. The frequency and quantity of rectal shedding did not differ between groups with/without oral lead-in. No correlation was observed between rectal shedding and detectable plasma HIV-1 RNA. Median rectal RPV concentration was 3.07 (quartile 1–quartile 3, 2.83–3.35) log10 ng/swab, 1.6-fold above the 90% maximum effective concentration (EC90) for rectal tissue, and did not correlate with rectal HIV-1 RNA levels. Rectal shedding was associated with plasma pre-ART HIV-1 RNA >5 log10 in multivariate Cox regression, but was unrelated to established predictors of virological failure with CAB/RPV.

Conclusions

Rectal HIV-1 shedding is common during bimonthly intramuscular CAB/RPV treatment and is also observed with oral ART. Shedding was independent of concurrent plasma HIV-1 RNA and rectal RPV concentrations, and was associated with pre-ART viral load.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirineHIV InfectionsHIV-1Virus SheddingPyridonesRectumAnti-HIV AgentsHumansMaleFemaleAdultProspective StudiesRNA, ViralMiddle AgedViral LoadInjections, IntramuscularDiketopiperazines

Stichwörter der Autor:innen

HIV transmission riskcabotegravirpharmacokineticrectal sheddingrilpivirine

Substanzen

RilpivirinecabotegravirRNA, ViralPyridonesAnti-HIV AgentsDiketopiperazines

Autor:innen und Institutionen

  • Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain.
  • Department of Clinical Medicine, Universidad Miguel Hernández, San Juan de Alicante, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain.
  • Institute for Research, Development, and Innovation in Health Biotechnology of Elche, Universidad Miguel Hernández, Elche, Spain.
  • Microbiology Service, Hospital General Universitario de Elche, Elche, Spain.

ORCID-Profile: Mar Masiá, Marta Fernández-González, Christian Ledesma, Maria Losada-Echeberría, Nieves Gonzalo-Jiménez, Paula Mascarell, Javier García-Abellán, Leandro López, Melissa Bello-Pérez, Sergio Padilla, Felix Gutiérrez

Förderung

  • Consorcio Centro de Investigación Biomédica en Red
  • Instituto de Salud Carlos III
  • Ministerio de Ciencia e Innovación
  • European Union

Zitieren

APA

Masiá, M., Fernández-González, M., Ledesma, C., Losada-Echeberría, M., Gonzalo-Jiménez, N., Mascarell, P., García-Abellán, J., López, L., Bello-Pérez, M., Padilla, S., & Gutiérrez, F. (2025). Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf117

Vancouver

Masiá M, Fernández-González M, Ledesma C, Losada-Echeberría M, Gonzalo-Jiménez N, Mascarell P, et al. Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf117

BibTeX
@article{Masi2025,
  author = {Masiá, Mar and Fernández-González, Marta and Ledesma, Christian and Losada-Echeberría, Maria and Gonzalo-Jiménez, Nieves and Mascarell, Paula and García-Abellán, Javier and López, Leandro and Bello-Pérez, Melissa and Padilla, Sergio and Gutiérrez, Felix},
  title = {Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf117}
}
Kostenlos starten →